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Abstract
Introduction: Interstitial Lung Disease (ILD) is frequently associated with Rheumatoid Arthritis (RA) as one of extra-articular
manifestations. Many studies for Human Leukocyte Antigen (HLA) allelic association with RA have been reported, but few
have been validated in an RA subpopulation with ILD. In this study, we investigated the association of HLA class II alleles
with ILD in RA.
Methods: An association study was conducted on HLA-DRB1, DQB1, and DPB1 in 450 Japanese RA patients that were or
were not diagnosed with ILD, based on the findings of computed tomography images of the chest.
Results: Unexpectedly, HLA-DRB1*04 (corrected P [Pc]=0.0054, odds ratio [OR] 0.57), shared epitope (SE) (P=0.0055, OR
0.66) and DQB1*04 (Pc=0.0036, OR 0.57) were associated with significantly decreased risk of ILD. In contrast, DRB1*16
(Pc=0.0372, OR 15.21), DR2 serological group (DRB1*15 and *16 alleles) (P=0.0020, OR 1.75) and DQB1*06 (Pc=0.0333, OR
1.57, respectively) were significantly associated with risk of ILD.
Conclusion: HLA-DRB1 SE was associated with reduced, while DR2 serological group (DRB1*15 and *16) with increased, risk
for ILD in Japanese patients with RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory
disease that affects about 1% of population and is associated with
the development of extra-articular manifestations. RA pathogen-
esis is multifactorial and the disease susceptibility is associated with
genetic and environmental factors [1,2,3]. Human Leukocyte
Antigen (HLA) is known to be associated with RA in most ethnic
groups. Some HLA-DR alleles are reported to be associated with
RA susceptibility [4]. A conserved amino acid sequence at position
70–74 (QKRAA, RRRAA, or QRRAA) in HLA-DRb chain is
shared between the RA-associated HLA-DR alleles; this was
designated as shared epitope (SE) [4]. Several studies have
reported the association of extra-articular manifestations of RA
with SE and DR4 subtype [5]. DRB1*04:01 and *04:05 were
associated with extra-articular manifestations of RA in European
and East Asian populations, respectively [6,7]. Extra-articular
manifestations of RA include pericarditis, pleuritis, Felty’s
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disease (ILD). DRB1*04:01 was strongly associated with Felty’s
syndrome in European population and a gene dosage effect was
noted [6,8].
ILD is frequently associated with RA or other collagen-
related diseases and named collagen vascular disease-associated
ILD (CVD-ILD). CVD-ILD in RA is one of the extra-articular
manifestations that influence the prognosis of RA [9]. Recent
study reported that median survival following diagnosis of ILD
was three years [10]. It is important to elucidate the
pathogenesis of ILD complicated with RA. Although association
of SE and extra-articular manifestations of RA was reported in
several populations, few studies have focused on ILD in RA
[11]. In this study, we investigated the association of HLA class
II with ILD in RA.
Materials and Methods
Patients and Controls
One hundred twenty nine RA patients with ILD (ILD positive
RA group) and 321 without ILD (ILD negative RA group) were
recruited at Sagamihara Hospital. Fifty seven healthy controls
were recruited at Sagamihara Hospital. In addition, 146
independent RA patients for replication study were recruited at
Kumamoto Center for Arthritis and Rheumatology, Nagasaki
Medical Center, and Yokohama Minami Kyosai Hospital. These
patients did not overlap with previous study participants [11,12].
All patients and healthy individuals were native Japanese living in
Japan. All patients with RA fulfilled the 1988 American College of
Rheumatology Criteria for RA [13]. This study was reviewed and
approved by the research ethics committees of each participating
institute, Sagamihara Hospital Research Ethics Committee,
Kumamoto Center for Arthritis and Rheumatology Research
Ethics Committee, Nagasaki Medical Center Research Ethics
Committee, Yokohama Minami Kyosai Hospital Research Ethics
Committee, and University of Tsukuba Research Ethics Commit-
tee. Written informed consent was obtained from all study
participants. This study was conducted in accordance with the
principles expressed in the Declaration of Helsinki.
RA patients were or were not diagnosed with ILD, based on the
findings of chest radiography or computed tomography (CT)
images. Images were reviewed by two physicians specializing in
CVD-ILD, and categorized from A to Z, according to the
Sagamihara Criteria as follows, A: Findings consistent with ILD,
including usual interstitial pneumonia (honeycombing), non-
specific interstitial pneumonia, and ground-glass attenuation
patterns, were observed in high resolution CT (HRCT) images
(length of shorter diameter of the lesion was $2 cm in a transverse
section) [14], B: In case HRCT images were unavailable, evidence
of ILD was found in conventional chest CT images (length of
shorter diameter of the lesion was $2 cm in a transverse section);
C: Evidence of ILD was observed in HRCT images (length of
shorter diameter of the lesion was ,2 cm in any transverse
section); D: If HRCT images were unavailable, evidence of ILD
was observed in conventional chest CT images (length of shorter
diameter of the lesion was ,2 cm in any transverse section); E: In
case CT images were unavailable, evidence of ILD was observed
in chest radiograms; F: In case CT images were unavailable,
abnormalities were not observed in chest radiograms; G: If HRCT
images were unavailable, abnormalities were not observed in
conventional chest CT images; H: HRCT images were normal; X:
Findings from lung HRCT images were predominantly other than
ILD, including bronchiectasis, bronchiolitis, emphysema, organiz-
ing pneumonia, tuberculosis, and cancer; Y: If HRCT images
were unavailable, findings from conventional chest CT images
were predominantly other than ILD; Z: If CT images were
unavailable, findings from chest radiograms were predominantly
other than ILD. In this study, RA cases in categories A to D were
diagnosed to be ‘‘ILD positive RA group’’ and those in G and H
were diagnosed to be ‘‘ILD negative RA’’. RA cases with other
collagen diseases or in categories E, F, X, Y, or Z were excluded
from this study. RA patients who visited Sagamihara Hospital
(n=2316) were classified as ILD positive RA (A to D; n=247,
10.7%) and ILD negative RA (G, H; n=431), according to the
available CT images (n=1034).
Rheumatoid Factor and anti-citrullinated peptide antibody
were detected using N-latex RF kit (Siemens Healthcare Diag-
nostics, Mu ¨nchen, Germany) and Mesacup-2 test CCP (Medical &
Biological Laboratories, Nagoya, Japan), respectively.
Genotyping
Genotyping of HLA-DRB1, DQB1, and DPB1 was performed by
polymerase chain reaction using sequence-specific oligonucleotide
probes, WAKFlow HLA typing kits (Wakunaga, Hiroshima,
Japan) using Bio-Plex 200 system (Bio-Rad, Hercules, CA), or by
MPH-2 HLA typing kits (Wakunaga). HLA-DRB1 alleles encoding
the SE were as follows: *01:01, *04:01, *04:04, *04:05, *04:10,
*10:01, *14:02, and *14:06 [4]. HLA-DRB1 locus of one RA
patient without ILD and HLA-DQB1 locus of one RA patient with
ILD failed to be typed. We then attempted to type these two loci
by Allele SEQR HLA-DRB1 and HLA-DQ sequence-based
Table 1. Characteristics of RA patients.
ILD(+)RA ILD(2)RA P
Number 129 321
Mean age, years (SD) 69.5 (7.8) 61.7 (11.2) *2.3610
215
Male, n (%) 42 (32.6) 47 (14.6) 1.6610
25
Current or past smokers, n (%) 42 (32.6) 88 (27.4) 0.2763
Disease duration, years (SD) 17.1 (12.2) 13.5 (10.1) *0.0041
Rheumatoid factor positive, n (%) 122 (94.6) 270 (84.1) 0.0027
Anti-citrullinated peptide antibody positive, n (%) 116 (89.9) 278 (86.6) 0.3349
Steinbrocker stage III and IV, n (%) 84 (65.1) 177 (55.1) 0.0525
ILD(+)RA: ILD positive RA, ILD(2)RA: ILD negative RA. Association was tested by chi-square analysis using 262 contingency tables or Student’s t-test.
*Student’s t-test was employed.
doi:10.1371/journal.pone.0033133.t001
HLA Association with ILD in RA
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were analyzed by Assign SBT v3.5 (Conexio Genomics, Perth,
Australia). Again, typing of these two loci failed, suggesting the
possibility of novel alleles. Previously reported results of HLA-
DRB1 genotyping for 265 healthy controls were combined with
our genotyping results and used for association analyses in this
study [12]. The phase of DRB1-DQB1 haplotype for each subject
was inferred by PHASE v2.1 [15,16].
Statistical Analysis
Differences of RA characteristics or allele frequencies were
analyzed by Student’s t-test, chi-square analysis or Fisher’s exact
test using 262 contingency tables. Adjustment for multiple
comparisons was performed using the Bonferroni method.
Corrected P (Pc) value was calculated by multiplying the P value
by the number of alleles tested. The sample size of this study (165
ILD positive RA patients and 432 ILD negative RA patients) had
the power of 80% to detect association when the genotype relative
risk was 0.71 or lower (SE) and 1.48 or higher (DR2), respectively
[17].
For the meta-analysis of HLA-DRB1, our data and previously
published data without overlap [11] were pooled using the
DerSimonian-Laird method with the random effects model [18].
Table 2. HLA class II allele frequency in the RA patients.
ILD(+)RA ILD(2)RA P OR Pc 95%CI
DRB1*01 21 (8.1) 44 (6.8) 0.5692 1.20 NS
DRB1*04 71 (27.5) 257 (40.1) 0.0004 0.57 0.005 (0.4120.78)
DRB1*07 0 (0) 2 (0.3) 1 0 NS
DRB1*08 11 (4.2) 38 (5.9) 0.4167 0.71 NS
DRB1*09 43 (16.6) 103 (16.0) 0.8419 1.04 NS
DRB1*10 2 (0.7) 5 (0.7) 1 0.99 NS
DRB1*11 3 (1.1) 8 (1.2) 1 0.93 NS
DRB1*12 13 (5.0) 30 (4.6) 0.8632 1.08 NS
DRB1*13 15 (5.8) 25 (3.9) 0.2141 1.52 NS
DRB1*14 18 (6.9) 32 (5.0) 0.2610 1.43 NS
DRB1*15 55 (21.3) 95 (14.8) 0.0228 1.55 0.296 (1.0722.25)
DRB1*16 6 (2.3) 1 (0.1) 0.0029 15.2 0.037 (1.822127.01)
DQB1*02 0 (0) 2 (0.3) 1 0 NS
DQB1*03 73 (28.5) 182 (28.3) 1 1.01 NS
DQB1*04 63 (24.6) 233 (36.2) 0.0007 0.57 0.004 (0.4120.79)
DQB1*05 38 (14.8) 77 (11.9) 0.2688 1.28 NS
DQB1*06 82 (32.0) 148 (23.0) 0.0067 1.57 0.033 (1.1422.17)
DPB1*02 70 (27.1) 206 (32.0) 0.1509 0.79 NS
DPB1*03 7 (2.7) 28 (4.3) 0.3400 0.61 NS
DPB1*04 42 (16.2) 103 (16.0) 0.9204 1.02 NS
DPB1*05 96 (37.2) 227 (35.3) 0.6448 1.08 NS
DPB1*06 1 (0.3) 5 (0.7) 0.6797 0.50 NS
DPB1*09 25 (9.6) 47 (7.3) 0.2766 1.36 NS
DPB1*13 5 (1.9) 7 (1.0) 0.3403 1.79 NS
DPB1*14 8 (3.1) 10 (1.5) 0.1846 2.02 NS
DPB1*17 0 (0) 1 (0.1) 1 0 NS
DPB1*19 2 (0.7) 3 (0.4) 0.6282 1.66 NS
DPB1*38 0 (0) 2 (0.3) 1 0 NS
DPB1*41 1 (0.3) 2 (0.3) 1 1.25 NS
DPB1*47 1 (0.3) 1 (0.1) 0.4914 2.49 NS
ILD(+)RA: ILD positive RA, ILD(2)RA: ILD negative RA, OR: odds ratio, 95%CI:
confidence interval, Pc: corrected P value, NS: not significant. Allele frequencies
are shown in parenthesis (%). Association was tested by Fisher’s exact test using
262 contingency tables.
doi:10.1371/journal.pone.0033133.t002
Table 3. HLA-DRB1 allele frequency in the RA patients.
ILD(+)RA ILD(2)RA P OR Pc 95%CI
DRB1*01:01 21 (8.1) 44 (6.9) 0.5692 1.20 NS
DRB1*04:01 6 (2.3) 28 (4.4) 0.1775 0.52 NS
DRB1*04:03 4 (1.6) 7 (1.1) 0.5224 1.42 NS
DRB1*04:04 0 (0) 1 (0.2) 1 0 NS
DRB1*04:05 56 (21.7) 194 (30.3) 0.0106 0.64 0.2872 (0.4520.90)
DRB1*04:06 2 (0.8) 10 (1.6) 0.5251 0.49 NS
DRB1*04:07 0 (0) 1 (0.2) 1 0 NS
DRB1*04:10 3 (1.2) 16 (2.5) 0.3055 0.46 NS
DRB1*07:01 0 (0) 2 (0.3) 1 0 NS
DRB1*08:02 1 (0.4) 12 (1.9) 0.1239 0.20 NS
DRB1*08:03 10 (3.9) 25 (3.9) 1 0.99 NS
DRB1*08:23 0 (0) 1 (0.2) 1 0 NS
DRB1*09:01 43 (16.7) 103 (16.1) 0.8419 1.04 NS
DRB1*10:01 2 (0.8) 5 (0.8) 1 0.99 NS
DRB1*11:01 3 (1.2) 8 (1.3) 1 0.93 NS
DRB1*12:01 7 (2.7) 21 (3.3) 0.8324 0.82 NS
DRB1*12:02 6 (2.3) 9 (1.4) 0.3881 1.67 NS
DRB1*13:02 15 (5.8) 25 (3.9) 0.2141 1.52 NS
DRB1*14:02 1 (0.4) 0 (0) 0.2873 7.46 NS
DRB1*14:03 4 (1.6) 3 (0.5) 0.1093 3.34 NS
DRB1*14:05 5 (1.9) 2 (0.3) 0.0234 6.30 0.6315 (1.22232.70)
DRB1*14:06 3 (1.2) 6 (0.9) 0.7215 1.24 NS
DRB1*14:07 0 (0) 1 (0.2) 1 0 NS
DRB1*14:54 5 (1.9) 20 (3.1) 0.3794 0.61 NS
DRB1*15:01 23 (8.9) 39 (6.1) 0.1459 1.51 NS
DRB1*15:02 32 (12.4) 56 (8.8) 0.1068 1.48 NS
DRB1*16:02 6 (2.3) 1 (0.2) 0.0029 15.21 0.0773 (1.822127.01)
DQB1*02:01 0 (0) 2 (0.3) 1 0 NS
DQB1*03:01 24 (9.4) 59 (9.2) 0.8993 1.02 NS
DQB1*03:02 5 (2.0) 33 (5.1) 0.0415 0.37 0.5813 (0.1420.95)
DQB1*03:03 43 (16.8) 89 (13.9) 0.2964 1.25 NS
DQB1*03:06 1 (0.4) 1 (0.2) 0.4891 2.51 NS
DQB1*04:01 60 (23.4) 215 (33.5) 0.0030 0.61 0.0423 (0.4420.85)
DQB1*04:02 3 (1.2) 18 (2.8) 0.2195 0.41 NS
DQB1*05:01 24 (9.4) 52 (8.1) 0.5953 1.17 NS
DQB1*05:02 6 (2.3) 16 (2.5) 1 0.94 NS
DQB1*05:03 8 (3.1) 9 (1.4) 0.1039 2.27 NS
DQB1*06:01 42 (16.4) 86 (13.4) 0.2463 1.27 NS
DQB1*06:02 25 (9.8) 38 (5.9) 0.0587 1.72 0.8224
DQB1*06:04 14 (5.5) 24 (3.7) 0.2709 1.49 NS
DQB1*06:09 1 (0.4) 0 (0) 0.2851 0 NS
ILD(+)RA: ILD positive RA, ILD(2)RA: ILD negative RA, OR: odds ratio, 95%CI:
confidence interval, Pc: corrected P value, NS: not significant. Allele frequencies
are shown in parenthesis (%). Association was tested by Fisher’s exact test using
262 contingency tables.
doi:10.1371/journal.pone.0033133.t003
HLA Association with ILD in RA
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e33133Lack of heterogeneity between the 2 populations was examined
using the Breslow-Day test of homogeneity.
To examine whether HLA-DRB1 and characteristics of RA
independently contributes to susceptibility to ILD in RA, multiple
logistic regression analysis was employed. Dominant, codominant
and recessive models were tested for SE or DR2, and the model
that provided the lowest P value was selected as the best fit model.
As a result, the following were used as independent variables: SE,
SE(2)/SE(2)=0, SE(+)/SE(2)=0 and SE(+)/SE(+)=1 under the
recessive model for SE; DR2, DR2(2)/DR2(2)=0, DR2(+)/
DR2(2)=1, DR2(+)/DR2(+)=1 under the dominant model for
DR2, respectively. The deviation from 0 was evaluated for partial
regression coefficients by the Wald test.
Results
Characteristics of ILD Positive RA and ILD Negative
RA Groups
Characteristics of ILD positive RA and ILD negative RA
groups were described in Table 1. Mean age, percentage of males,
disease duration, and positivity of rheumatoid factor in ILD
positive RA group were higher than that of ILD negative RA
group. The difference of smoking habit, anti-citrullinated peptide
antibody, or Steinbrocker stage was not detected.
Association of HLA-DR and DQ with ILD
We tested whether HLA class II was associated with ILD in the
comparison of ILD positive RA and ILD negative RA groups.
Low-resolution and high-resolution typing data are shown in
Table 2 and 3, respectively. A significant association was found for
DRB1*04 alleles with resistance to ILD (Pc=0.0054, odds ratio
[OR] 0.57, 95% confidence interval [CI] 0.4120.78, Table 2). On
the other hand, DRB1*16 allele (DRB1*16:02 in the high-
resolution typing) was associated with susceptibility to ILD
(Pc=0.0372, OR 15.21, 95%CI 1.822127.01, Table 2 and 3).
HLA-DQB1*04 allele was also associated with resistance to ILD
(Pc=0.0036, OR 0.57, 95%CI 0.4120.79). DQB1*06 allele was
associated with susceptibility to ILD (Pc=0.0333, OR 1.57,
95%CI 1.1422.17). Thus, there was an association of HLA-DR
and DQ with the susceptibility or resistance to ILD in RA patients.
We then compared the allele frequency of HLA-DR in ILD
positive RA group with healthy controls (Table 4). Although
DRB1*04, *08, *13, and *14 were associated with ILD negative
RA, association of DRB1*04 with ILD positive RA was not
observed.
The DRB1 and DQB1 alleles which showed significant
association are in strong linkage disequilibrium. In order to
elucidate which of the DRB1 and DQB1 was responsible for the
association, haplotype analysis of DRB1-DQB1 was performed.
Influence of the presence or absence of a haplotype on ILD
phenotype was analyzed by Fisher’s exact test using 262
contingency tables under the dominant model. DRB1*16:02-
DQB1*05:02 was significantly associated with ILD positive RA
(n=4 [1.6%] in ILD positive RA vs. n=1 [0.2%] in ILD negative
RA, P=0.0257, OR 10.09), but DRB1*14:54-DQB1*05:02 was
not (n=2 [0.8%] in ILD positive RA vs. n=13 [2%] in ILD
negative RA, P=0.2544, OR 0.38). The two-locus analysis was
also performed to clarify the primary role of DRB1*16:02 or
DQB1*05:02. OR for DRB1*16:02 in the patients without
DQB1*05:02 was 12.61, while OR for DQB1*05:02 in the patients
without DRB1*16:02 was 0.36 (Table 5). The difference did not
reach statistical significance, because the strong linkage disequi-
librium between DRB1*16:02 and DQB1*05:02 causes the low
frequency of DRB1*16:02 in the patients without DQB1*05:02 and
that of DQB1*05:02 in the patients without DRB1*16:02. Thus,
haplotype and two-locus analysis suggested the primary role of
DRB1*16:02.
Association of SE and DR2 with ILD
The effect of SE on ILD in RA was evaluated. Frequency of SE
alleles was lower in ILD positive RA group compared with ILD
negative RA group (P=0.0055, OR 0.66, 95%CI 0.4920.88).
This association was also observed in the genotype frequency of
SE under the recessive model (P=0.0012, OR 0.31, 95%CI
0.1520.65). However, the association was not confirmed under
the dominant model (P=0.0968, OR 0.69, 95%CI 0.4521.07),
Table 4. HLA-DRB1 allele frequency in the RA patients and controls.
ILD(+)RA ILD(2)RA Control (ILD(+)RA vs Control) 95%CI (ILD(2)RA vs Control) 95%CI
P OR Pc P OR Pc
DRB1*01 21 (8.1) 44 (6.9) 29 (4.5) 0.0364 1.88 0.4370 (1.0523.36) 0.0712 1.57 0.8547
DRB1*04 71 (27.5) 257 (40.2) 150 (23.3) 0.1989 1.25 NS 8.1610
211 2.21 9.7610
210 (1.7422.81)
DRB1*07 0 (0) 2 (0.3) 2 (0.3) 1 0 NS 1 1.01 NS
DRB1*08 11 (4.3) 38 (5.9) 70 (10.9) 0.0012 0.37 0.014 (0.1920.70) 0.0017 0.52 0.0207 (0.3420.78)
DRB1*09 43 (16.7) 103 (16.1) 105 (16.3) 0.9208 1.03 NS 0.9397 0.98 NS
DRB1*10 2 (0.8) 5 (0.8) 2 (0.3) 0.3236 2.51 NS 0.2864 2.53 NS
DRB1*11 3 (1.2) 8 (1.3) 7 (1.1) 1 1.07 NS 0.8019 1.15 NS
DRB1*12 13 (5.0) 30 (4.7) 35 (5.4) 0.8711 0.92 NS 0.6110 0.86 NS
DRB1*13 15 (5.8) 25 (3.9) 68 (10.6) 0.0296 0.52 0.356 (0.2920.93) 4.4610
26 0.34 5.2610
25 (0.2120.55)
DRB1*14 18 (7.0) 32 (5.0) 61 (9.5) 0.2967 0.72 NS 0.0024 0.50 0.0291 (0.3220.78)
DRB1*15 55 (21.3) 95 (14.8) 107 (16.6) 0.1031 1.36 NS 0.3998 0.87 NS
DRB1*16 6 (2.3) 1 (0.2) 8 (1.2) 0.2416 1.89 NS 0.0384 0.12 0.4610 (0.0221.00)
SE(+) 92 (35.7) 294 (45.9) 145 (22.5) 0.0001 1.91 (1.3922.61) 9.0610
219 2.92 (2.3023.72)
ILD(+)RA: ILD positive RA, ILD(2)RA: ILD negative RA, OR: odds ratio, 95%CI: confidence interval, Pc: corrected P value, NS: not significant. Allele frequencies are shown in
parenthesis (%). Association was tested by Fisher’s exact test using 262 contingency tables.
doi:10.1371/journal.pone.0033133.t004
HLA Association with ILD in RA
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development in RA. The effect of DR2 serological group,
consisting of DRB1*15, and 16, on ILD in RA was also evaluated.
Frequency of DR2 alleles was higher in ILD positive RA
compared with ILD negative RA group (P=0.0020, OR 1.75,
95%CI 1.2222.51). Association with DR2 was also observed
under the dominant model (P=0.0007, OR 2.06, 95%CI
1.3523.16).
We then made an attempt to confirm these associations in an
independent set of ILD positive RA and ILD negative RA. The
frequency of SE alleles was lower in ILD positive RA group
compared with ILD negative RA group (24 [33.3%] in ILD
positive RA vs. 84 [38.2%] in ILD negative RA, P=0.4595, OR
0.81, 95%CI 0.4621.42), although the difference did not reach
significance. On the other hand, significant increase of DR2 alleles
in ILD positive RA was replicated (20 [27.8%] in ILD positive RA
vs. 37 [16.8%] in ILD negative RA, P=0.0417, OR 1.90, 95%CI
1.0223.55). When these data were combined with that of RA
patients from Sagamihara hospital, both the protective association
of SE (P=0.0064, OR 0.69, 95%CI 0.5320.90, Table 6) and the
positive association of DR2 group (P=0.0002, OR 1.78, 95%CI
1.3122.43, Table 6) remained significant.
Meta-analysis of these data combined with the data from the
previous report [11] showed the protective association of SE
(pooled P=0.0069, OR 0.72, 95%CI 0.5720.92) and the positive
association of DR2 group (pooled P=0.0001, OR 1.96, 95%CI
1.3922.75). Breslow-Day test confirmed the lack of heterogeneity
between our data and the previously reported data on SE and
DR2 (P=0.4848 and 0.2767, respectively).
WethenexaminedwhethertheprotectiveeffectofSEissecondary
to the increase of DR2 group in the ILD positive RA group, by
excludingpatientswithDR2fromtheanalysis.SEwasstillassociated
with resistance to ILD (P=0.0270, OR 0.69, 95%CI 0.4920.96,
Table 6), indicating that the protective association of SE was not
caused by the positiveassociation of DR2.
We examined whether the positive association of DR2 group is
secondary to the decrease of SE in the ILD positive RA patients.
When the patients with SE were excluded from the analysis, the
DR2 allele frequency was still higher in ILD positive RA than ILD
negative RA, although the effect was not statistically significant
(P=0.1108, OR 1.46, 95%CI 0.9222.32, Table 6).
To examine the independent contribution of SE and character-
istics of RA to susceptibility to ILD, multiple logistic regression
analysis was conducted. The association of age (P=2.2610
27,O R
1.08,95%CI1.0521.12),malegender(P=0.0003,OR3.60,95%CI
1.8127.18) and SE (P=0.0091, OR 0.34 95%CI 0.1520.76) with
ILD was significant. On the other hand, significant association of
smoking habit, disease duration, rheumatoid factor, anti-citrulli-
nated peptide antibody, or Steinbrocker stage with ILD was not
observed. Similar results were obtained from the multiple logistic
regressionanalysisonDR2andcharacteristicsofRA.Theassociation
of age (P=1.0610
27, OR 1.09, 95%CI 1.0521.12), male gender
(P=0.0005,OR3.39,95%CI1.7126.71)andDR2(P=0.0080,OR
2.0295%CI1.2023.40)withILDremainedsignificant,thoughthat
of smoking habit, disease duration, rheumatoid factor, anti-
citrullinated peptide antibody, or Steinbrocker stage with ILD was
not observed.
Discussion
Several studies have shown that HLA-DR contributes to the
susceptibility to extra-articular manifestations of RA. The associ-
ation of Felty’s syndrome, one of extra-articular manifestations of
RA, with SE was reported [5]. However, few studies have focused
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HLA Association with ILD in RA
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e33133on the association of HLA with ILD in RA, one of the potentially
life-threatening extra-articular manifestations. To our knowledge,
this is the first report of association of the SE with an obvious
protective effect for ILD in RA, although a weak protective effect
by SE for ILD in RA was previously observed [11,19]. Our
findings suggest different pathogenic mechanisms between ILD
and Felty’s syndrome in RA.
When SE frequency in ILD positive RA group was compared
with healthy controls, the frequency of SE alleles was still
significantly higher in ILD positive RA group (P=0.0001, OR
1.91, 95%CI 1.3922.61 under the allele model, Table 4,
P=1.7610
26, OR 2.77, 95%CI 1.8124.23 under the dominant
model); however, the association was considerably weaker as
compared with ILD negative RA (P=9.0610
219, OR 2.92,
95%CI 2.3023.72 under the allele model, Table 4,
P=3.3610
217, OR 4.05, 95%CI 2.9025.64 under the domi-
nant model). Although the implication of this finding is not
clear, this might suggest that the role of SE may not be as
important in ILD positive RA as compared with RA per se.
Environmental triggers might play a substantial role in the
development of ILD. Alternatively, the genetic background of
ILD positive RA and ILD negative RA groups may be
different, and genetic factors other than SE may play a
significant role in the former. Significantly higher proportion of
male patients in ILD positive RA might support this possibility.
Such possibilities are not mutually exclusive, and some of them
are currently being tested.
The association of DRB1*15:02 and ILD in RA has been
reported in the Japanese population [11]. Notably, DRB1*15:01
and *16:02 frequency was higher in idiopathic pulmonary fibrosis
patients [20,21]. DRB1*15, and 16 belong to the DR2 serological
group. DR2 was reported to be the susceptibility allele of systemic
lupus erythematosus [22], other autoimmune diseases, and other
extra-articular manifestations in RA [23,24]. The association of
DR2 with ILD in RA was also confirmed in our study. A common
peptide (DENPVVHFFKNIVTPRTPP) is known to be presented
by DRB1*15:01 and 16:02, explaining the susceptibility of DR2
positive individuals for ILD in RA [25].
Although DRB1*11 was reported to be associated with
pulmonary fibrosis in European systemic sclerosis patients [26],
this association was not confirmed in our study. This could be
explained by the differences in the pathogenesis of ILD in RA and
systemic sclerosis, ethnic difference, or both. At this point, we
cannot rule out the possibility that another causative genes might
exist in the HLA region in linkage disequilibrium with the culprit
gene in the DR locus. This possibility could be addressed by re-
sequencing the entire HLA region of DRB1*16:02 allele.
The logistic regression analysis indicated that the association of
age and gender with ILD in RA. These data suggested the
existence of a subset of RA with older age at onset and higher ratio
of male that is susceptible for ILD. Because of the limited sample
size of this study, the observed statistical association was modest.
The association of HLA-DR should be confirmed in future
independent studies. Since the allelic distribution of HLA in other
ethnic populations is different from that in the Japanese, the role of
HLA-DR for ILD in RA in other populations should be
determined.
This is the first identification of association of HLA-DR*16 with
susceptibility to, and that of the SE with resistance to ILD in RA.
Our findings support the role of HLA-DR in CVD-ILD
pathogenesis.
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Table 6. SE and DR2 frequency in the all RA patients and RA patients without SE or DR2.
Allele frequency Genotype frequency Allelic association Dominant model Recessive model
SE(+)S E ( 2) SE(+)/SE(+)
SE(+)/
SE(2)
SE(2)/
SE(2) P OR (95%CI) P OR (95%CI) P OR (95%CI)
All RA patients
ILD(+)RA 116 (35.2) 214 (64.8) 11 (6.7) 94 (57.0) 60 (36.4) 0.0064 0.69 (0.5320.90) 0.1172 0.74 (0.5121.08) 0.0008 0.34 (0.1820.66)
ILD(-)RA 378 (43.9) 484 (56.1) 75 (17.4) 228 (52.9) 128 (29.7)
RA patients
without DR2
ILD(+)RA 77 (41.8) 107 (58.2) 11 (12.0) 55 (59.8) 26 (28.3) 0.0270 0.69 (0.4920.96) 0.2257 0.72 (0.4321.22) 0.0107 0.42 (0.2120.83)
ILD(-)RA 314 (51.1) 300 (48.9) 75 (24.4) 164 (53.4) 68 (22.1)
DR2(+) DR2(2) DR2(+)/
DR2(+)
DR2(+)/
DR2(2)
DR2(2)/
DR2(2)
All RA patients
ILD(+)RA 81 (24.5) 249 (75.5) 8 (4.8) 65 (39.4) 92 (55.8) 0.0002 1.78 (1.3122.43) 0.0003 1.96 (1.3622.85) *0.0955 2.39 (0.9126.30)
ILD(-)RA 133 (15.4) 729 (84.6) 9 (2.1) 115 (26.7) 307 (71.2)
RA patients
without SE
ILD(+)RA 42 (35.0) 78 (65.0) 8 (13.3) 26 (43.3) 26 (43.3) 0.1108 1.46 (0.9222.32) 0.2107 1.48 (0.8022.75) 0.1602 2.03 (0.7425.57)
ILD(-)RA 69 (27.0) 187 (73.0) 9 (7.0) 51 (39.8) 68 (53.1)
ILD(+)RA: ILD positive RA, ILD(2)RA: ILD negative RA, OR: odds ratio, 95%CI: confidence interval, SE: Shared epitope. Genotype or allele frequencies are shown in
parenthesis (%). Association was tested by chi-square analysis or Fisher’s exact test using 262 contingency tables under the indicated models for SE or DR2. *Fisher’s
exact test was employed.
doi:10.1371/journal.pone.0033133.t006
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